# A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

> **NCT07743671** · PHASE3 · RECRUITING · sponsor: **Vaderis Therapeutics AG** · enrollment: 240 (estimated)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia

## Interventions

- **DRUG:** Engasertib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07743671
- **Lead sponsor:** Vaderis Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743671, "A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*